These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7513417)

  • 1. Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide.
    Cusan L; Gomez JL; Dupont A; Diamond P; Lemay M; Moore S; Labrie F
    Prostate; 1994 May; 24(5):257-61. PubMed ID: 7513417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma.
    Dupont A; Labrie F; Giguere M; Borsanyi JP; Lacourciere Y; Bergeron N; Cusan L; Belanger A; Emond J
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):659-66. PubMed ID: 3289945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
    J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
    Labrie F; Dupont A; Belanger A; Lachance R
    J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
    Labrie F; Dupont A; Cusan L; Giguere M; Bergeron N; Borsanyi JP; Lacourciere Y; Belanger A; Emond J; Monfette G
    J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide.
    Bélanger A; Giasson M; Couture J; Dupont A; Cusan L; Labrie F
    Prostate; 1988; 12(1):79-84. PubMed ID: 3279409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report].
    Fukuda M; Takashima H; Fuse H; Hirano S
    Hinyokika Kiyo; 2002 Aug; 48(8):499-502. PubMed ID: 12243078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma.
    Dupont A; Cusan L; Gomez JL; Koutsilieris M; Suburu R; Emond J; Labrie F
    Br J Urol; 1993 Nov; 72(5 Pt 1):629-34. PubMed ID: 10071551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
    Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Urology; 1995 May; 45(5):745-52. PubMed ID: 7538237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mediastinal lymph nodes during the course of a metastatic prostate cancer].
    Roca Edreira A; Aguilera Tubet C; Villanueva Peña A; Ballestero Diego R; Zubillaga Guerrero S
    Actas Urol Esp; 2007 Jun; 31(6):693-5; discussion 695. PubMed ID: 17896567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
    Soloway MS; Schellhammer P; Sharifi R; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Eur Urol; 1996; 29 Suppl 2():105-9. PubMed ID: 8717471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
    Scher HI; Kelly WK
    J Clin Oncol; 1993 Aug; 11(8):1566-72. PubMed ID: 7687666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
    Small EJ; Srinivas S
    Cancer; 1995 Oct; 76(8):1428-34. PubMed ID: 8620419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
    Slovin SF
    Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
    Redding TW; Schally AV
    Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
    Figg WD; Kroog G; Duray P; Walther MM; Patronas N; Sartor O; Reed E
    Cancer; 1997 May; 79(10):1964-8. PubMed ID: 9149024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
    Labrie F; Candas B; Gomez JL; Cusan L
    Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.